Protective effect of erythropoietin on torsion/detorsion injury in rat model.
OBJECTIVE
The aim of the study is to investigate the effects of erythropoietin on torsion/detorsion injury in rats.


METHODS
Forty rats were divided randomly into 5 groups: group I (sham, S), sham operation; group II (torsion/detorsion 1, T/D(1)), 3 hours ischemia and 1 hour reperfusion; group III (torsion/detorsion 2, T/D(2)), 3 hours ischemia and 48 hours reperfusion; group IV (erythropoietin 1, EPO(1)), 3 hours ischemia, 1 hour reperfusion, and a single dose of EPO; and group V (erythropoietin 2, EPO(2)), 3 hours ischemia, 48 hours reperfusion, and 2 doses of EPO. Malondialdehyde (MDA) and nitric oxide (NO) levels and activities of superoxide dismutase and catalase were measured. Tissue damage to ovarian tissue was scored by histologic examination. Data were compared among groups with parametric tests.


RESULTS
The MDA levels in the S and EPO groups were significantly lower than the T/D groups (P < .001). Catalase and superoxide dismutase activities, and NO levels in the S and EPO groups were significantly higher than in the T/D groups (P < .05). Ovarian tissue damage in the S and EPO groups was significantly less than in the T/D groups (P < .05). Levels of all biochemical markers and ovarian tissue damage scores were similar among the S, EPO(1), and EPO(2) groups (P > .05).


CONCLUSIONS
Erythropoietin attenuates ischemia-reperfusion injury when given during the acute phase of ovarian torsion-detorsion in a rat model.
Bakan
Vedat
V
Faculty of Medicine, Department of Pediatric Surgery, Sutcu Imam University, Kahramanmaras 46100, Turkey. vedatbakan@hotmail.com
Ciralik
Harun
H
Tolun
Fatma Inanaç
FI
Atli
Yalçin
Y
Mil
Ayhan
A
Oztürk
Senol
S
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D002374:Catalase / Q000378:metabolism; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D008315:Malondialdehyde / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D010049:Ovarian Diseases / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism; D014102:Torsion Abnormality / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*
D000975:Antioxidants; D011994:Recombinant Proteins; D004921:Erythropoietin; D009569:Nitric Oxide; D008315:Malondialdehyde; D002374:Catalase; D013482:Superoxide Dismutase